Opaganib
{{Short description|Chemical compound}}
{{Drugbox
| IUPAC_name = 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
| image = Opaganib_structure.png
| tradename =
| legal_US =
| legal_status = Investigational new drug
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number = 915385-81-8
| PubChem = 15604015
| UNII = DRG21OQ517
| ChemSpiderID = 13079494
| DrugBank = 12764
| ChEMBL = 2158685
| ChEBI = 124965
| C=23 | H=25 | Cl=1 | N=2 | O=1
| SMILES = C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl
| StdInChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27)
| StdInChIKey = CAOTVXGYTWCKQE-UHFFFAOYSA-N
}}
Opaganib (ABC294640) is a drug which acts as an inhibitor of the enzyme sphingosine kinase 2, dihydroceramide desaturase (DES1), and glucosylceramide synthase (GCS).{{cite journal |vauthors=Smith CD, Maines LW, Keller SN, Katz Ben-Yair V, Fathi R, Plasse TF, Levitt ML |title=Recent Progress in the Development of Opaganib for the Treatment of Covid-19 |journal=Drug Design, Development and Therapy |volume=16 |issue= |pages=2199–2211 |date=2022 |pmid=35855741 |pmc=9288228 |doi=10.2147/DDDT.S367612|doi-access=free }} It is under development as a potential treatment agent for several different kinds of cancer.{{cite journal | vauthors = Camp ER, Patterson LD, Kester M, Voelkel-Johnson C | title = Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer | journal = Cancer Biology & Therapy | volume = 18 | issue = 9 | pages = 640–650 | date = September 2017 | pmid = 28686076 | doi = 10.1080/15384047.2017.1345396 | pmc = 5663409 }}{{cite journal | vauthors = Lewis CS, Voelkel-Johnson C, Smith CD | title = Targeting Sphingosine Kinases for the Treatment of Cancer | journal = Advances in Cancer Research | year = 2018 | volume = 140 | pages = 295–325 | pmid = 30060814 | doi = 10.1016/bs.acr.2018.04.015 | pmc = 6447312 | isbn = 9780128142233 }} Opaganib has also demonstrated antiviral activity against SARS-CoV-2 and has shown a reduction in mortality among patients with moderately severe COVID-19 in a multinational Phase 2/3 clinical trial and also appeared to exhibiting anti-inflammatory effects by reducing levels of IL-6 and TNF-alpha.{{cite web |vauthors=Bergman SJ |title=COVID-19 Treatment: Investigational Drugs and Other Therapies: Introduction, Antiviral Agents, Immunomodulators and Other Investigational Therapies |website=Medscape |date=31 December 2024 |url=https://emedicine.medscape.com/article/2500116-overview |access-date=26 January 2025}}